Market Research Logo

Restenosis - Pipeline Review, H2 2016

Restenosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Restenosis - Pipeline Review, H2 2016’, provides an overview of the Restenosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restenosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Restenosis
    • The report reviews pipeline therapeutics for Restenosis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Restenosis therapeutics and enlists all their major and minor projects
    • The report assesses Restenosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Restenosis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Restenosis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Restenosis Overview
    Therapeutics Development
    Pipeline Products for Restenosis - Overview
    Pipeline Products for Restenosis - Comparative Analysis
    Restenosis - Therapeutics under Development by Companies
    Restenosis - Therapeutics under Investigation by Universities/Institutes
    Restenosis - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Restenosis - Products under Development by Companies
    Restenosis - Products under Investigation by Universities/Institutes
    Restenosis - Companies Involved in Therapeutics Development
    Bio3 Research S.r.l
    CytoTools AG
    XBiotech Inc
    Restenosis - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (connective tissue growth factor + insulin human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alendronate sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CV-18C3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    didox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HMW-02Ak - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HMW-02Ap - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HO-3867 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TW-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Restenosis - Dormant Projects
    Restenosis - Discontinued Products
    Restenosis - Product Development Milestones
    Featured News & Press Releases
    Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis
    Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease
    Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites
    Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Restenosis, H2 2016
    Number of Products under Development for Restenosis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Restenosis - Pipeline by Bio3 Research S.r.l, H2 2016
    Restenosis - Pipeline by CytoTools AG, H2 2016
    Restenosis - Pipeline by XBiotech Inc, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Restenosis - Dormant Projects, H2 2016
    Restenosis - Dormant Projects (Contd..1), H2 2016
    Restenosis - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Restenosis, H2 2016
    Number of Products under Development for Restenosis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report